Vir Biotechnology Announces Partnership With Glaxo Against Covid New Variant

Vir Biotechnology and Glaxo have joined together to supply the US government with 600,000 supplementary doses of Sotrovimab. It is expected to finish by the first half of 2022. Sotrovimab was approved by the USFDA last May to treat COVID-19 in high-risk adult and pediatric patients with severe or fatal infections. At the end of 2021, the companies confirmed great withstand against the COVID-19 “Omicron” variant. Through this agreement, Glaxo and Vir are able to secure additional doses of Sotrovimab for the US government. They also fixed partnerships with other international organizations to supply sotrovimab.

Vir Biotechnology

The press release resulted in the decision that Glaxo and Vir can produce up to 2 million doses to end in the second quarter. As part of the partnership, Vir and Glaxo also agreed to extend the contract for the supply of sotrovimab to the US government. The partnership is favorable for both Vir Biotechnology and Glaxo. It will allow Vir to continue to receive the sotrovimab doses it needs.